[Modification of the toxic effects of cis-dichlorodiammineplatinum].
It is established that the preparation K-2-9 being administered in combination with cis-dichlorodiaminoplatinum (DDP) lowers the DDP toxic effects, in particular nephrotoxicity and enterotoxicity, increases the activity of the enzymes participating in microsomal liver oxidation, the activity of kidney transamidinase, the quantity of SH-groups of the liver and kidney tissue, intensifies the antitumour effect of DDP.
D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats
D002945:Cisplatin
Modifikatsiia toksicheskikh éffektov tsis-dikhlordiamminoplatiny.